Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression related to tumor infiltrating lymphocytes status and BRAFV600E status in naive melanoma cancer patients

ABSTRACT: Gene expression profiling of a total of 770 genes included in the PanCancer IO 360™ panel+ 20 genes of interest were studied in 198 melanomas cases and correlated to TILS and BRAF600E mutation status

ORGANISM(S): Homo sapiens

PROVIDER: GSE193802 | GEO | 2022/08/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Mammary Tumor-Derived Transplants as Breast Cancer Models to Evaluate Tumor-Immune Interactions and Therapeutic Responses

Project description:To investigate mTDT transcriptional features using the Nanostring pancancer io 360 gene expression panel that consists of 770 unique genes involved in the interplay between the tumor, microenvironment and immune response.

2021-12-01 | GSE152403 | GEO

Gene expression of human angiosarcoma and correlation with treatment outcomes

Project description:Gene expression profiling of human angiosarcoma samples was performed using the NanoString Human nCounter PanCancer IO 360 Panel

2020-12-01 | GSE162370 | GEO

Gene expression of human angiosarcoma

Project description:Gene expression profiling of human angiosarcoma samples was performed using the NanoString Human nCounter PanCancer IO 360 Panel

2023-05-03 | GSE226338 | GEO

Transcriptomic analyses of NF1-mutant melanoma

Project description:RNA analysis of 770 genes (Pan Cancer IO 360) related to the tumor microenvironment on NF1-MUT and matched NF1-WT samples for reference.

2022-05-12 | GSE202806 | GEO

Spatial analysis reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates in pediatric acute myeloid leukemia [Nanostring PanCancer IO 360]

Project description:Comparison of immune-infiltrated bone marrow samples (n=6) with immune-depleted bone marrow samples (n=17) of pediatric acute myeloid leukemia patients using the Nanostring PanCancer IO 360 panel.

2024-08-27 | GSE228481 | GEO

CCA NanoString data (60CCA)

Project description:Raw .RCC files for NanoString. nCounter PanCancer IO 360 Panel was used

| EGAD00010002612 | EGA

NanoString Human PC3 nCounter PanCancer IO 360 panel

Project description:NanoString Human PC3 nCounter PanCancer IO 360 panel

| PRJNA772256 | ENA

Identification of mode of action for cell-based immunotherapy with ex-vivo expanded and activated autologous killer cells (AKCs) to recurrent glioblastoma (GBM) patients

Project description:The 12 recurrent GBM patients were participated. NanoString nCounter pancancer IO 360 panel (750 genes) assay was conducted with GBM patients tissue which was extracted at postoperative after recurrent event. The goal of this study was to extract significant genes which were associated with overall survival (OS) and durable response within AKC-treated recurrent GBM patients.

2020-12-31 | GSE142693 | GEO

NanoString PanCancer Immune Profiling of 4′‐bromo‐resveratrol treated BrafV600E/PtenNULL melanoma mice

Project description:We performed differential gene expression analysis using high throughput multiplex analysis via NanoString nCounter PanCancer Immune Profiling panel, which analyzes 770 genes related to cancer-immune pathways (cancer progression, chemokines and cytokines and their receptors, and innate and adaptive immune response). nSolver software was used to analyze the data and a heat map was generated to show differential expression of 770 genes. Further, using a fold cut-off of ≥2 and p-value <0.05, we observed that 4'-BR significantly modulated expression of multiple cancer immune genes.

2021-11-29 | GSE168564 | GEO

Cancer-immune expressional variation in glioblastoma second surgery samples to compare progression and pseudoprogression

Project description:We performed cancer-immune gene expression analysis on a case series of glioblastoma second surgery samples due to novel enhancement following chemoradiation that were confirmed based on clinico-pathologic outcome as disease progression (PD) or pseudoprogression (psPD). This was accomplished using an nCounter Pancancer 360 IO panel. Our goals were to (1) determine if psPD events could be distinguished from PD events using differences in immune cell activation versus cancer cell proliferation and (2) examine whether samples stratified based on their molecular profile in the same way as documented clinico-pathologic diagnosis.

2023-12-04 | GSE231994 | GEO